@FierceMedDev: Wright buying implant outfit for $80M with eye on Europe. ICYMI yesterday | Follow @FierceMedDev
@MarkHFierce: Roche is closing down its 454 Life Sciences gene sequencing division. FierceDiagnostics story | Follow @MarkHFierce
@MichaelGFierce: ICYMI: FierceMedicalDevices' 2013 Fierce 15. Special report | Follow @MichaelGFierce
> GE Healthcare ($GE) boosted its third-quarter profits despite flat sales. Story
> For the third time, the FDA has rejected Alimera Sciences ($ALIM) and pSivida's ($PSDV) Iluvien, a back-of-the-eye implant that delivers a drug to treat diabetic vision loss. Story
> U.S.-based National Instruments has signed a memorandum of understanding with The Healthcare Technology Innovation Center in India to develop new, affordable medical devices. Story
> Researchers from Columbia University Medical Center found in a study that a narrow spectrum of UV light was effective in killing bacteria such as MRSA and didn't harm human skin. Item
> A new study concludes that CT and MRI machines are overused for headaches, despite recommendations against the practice. Story
> General Electric is seeking a patent for an electromagnetic system that would be designed to detect medical instruments in use during surgery, spotting where they are within a patient during a procedure. Story
Biotech News
@FierceBiotech: VC funding follows tepid pace in Q3 as first-time rounds shrivel. Special report | Follow @FierceBiotech
@JohnCFierce: Seamus Fernandez is downgrading Sanofi. Likes PCSK9 but thinks prospects are overblown. Lotso competition coming. Very sensible assessment. | Follow @JohnCFierce
@DamianFierce: The third time is not whatsoever charming as Alimera, pSivida get another FDA rejection for Iluvien. Article | Follow @DamianFierce
@EmilyMFierce: Mini pancreas grown in lab using mouse cells. Story from FierceBiotech Research | Follow @EmilyMFierce
> Boehringer snags EU nods for COPD drug as FDA awaits. More
> Bullish Relypsa eyes $138M in bumped-up IPO pitch. Story
> Blood clots force Ariad to shutter PhIII Iclusig trial. Article
Pharma News
@FiercePharma: Biggest story this a.m. online: Pharma dealmakers, listen up; Ireland may close a popular tax loophole. Story | Follow @FiercePharma
@EricPFierce: Another gut check for Amarin and its fish oil drug Vascepa. FDA panel votes against wider use. Article | Follow @EricPFierce
@CarlyHFierce: Q3 earnings: Abbott ups dividend, Actelion confirms growth, Baxter hurt by merger costs. More | Follow @CarlyHFierce
> Valeant ordered to pay Anacor $100M. Story
> EP Vantage: Eliquis projected sales off 60% for 2014. Article
> NICE panel likes Astellas' Xtandi. More